Skip to main content

Advertisement

Table 2 Association between eight SNPs and T2D in Thai population

From: Impact of KCNQ1, CDKN2A/2B, CDKAL1, HHEX, MTNR1B, SLC30A8, TCF7L2, and UBE2E2 on risk of developing type 2 diabetes in Thai population

Gene SNP (major/minor alleles*) aRisk allele freq. bRisk allele freq. Subject Genotype frequency, n (%) Additive model Dominant model Recessive model
P unadjusted
OR (95% CI)
P adjusted
OR (95% CI)
P unadjusted
OR (95% CI)
P adjusted
OR (95% CI)
P unadjusted
OR (95% CI)
P adjusted
OR (95% CI)
A/A A/B B/B
KCNQ1 rs2237892
(C > T)
0.76 0.71 Patient 285 (57.0) 192 (38.4) 23 (4.6) 0.060
1.74 (0.99–3.07)
0.020
2.02 (1.08–3.79)
0.128
1.53 (0.88–2.66)
0.057
1.83 (0.98–3.42)
0.025
1.36 (1.04–1.78)
0.018
1.43 (1.06–1.92)
Control 254 (50.8) 205 (41.0) 41 (8.2)
CDKN2A/2B rs10811661
(T > C)
0.68 0.62 Patient 228 (45.6) 220 (44.0) 52 (10.4) 0.100
1.45 (0.93–2.27)
0.044
1.65 (1.01–2.71)
0.227
1.29 (0.85–1.96)
0.105
1.46 (0.92–2.31)
0.077
1.28 (0.97–1.69)
0.066
1.33 (0.98–1.81)
Control 185 (37.0) 248 (49.6) 67 (13.4)
SLC30A8 c rs13266634
(C > T)
0.59 0.54 Patient 172 (34.4) 242 (48.4) 86 (17.2) 0.040
1.51 (1.01–2.21)
0.006
1.86 (1.19–2.90)
0.309
1.20 (0.84–1.71)
0.191
1.29 (0.87–1.91)
0.008
1.48 (1.11–1.98)
0.0003
1.81 (1.31–2.50)
Control 137 (27.4) 268 (53.6) 95 (19.0)
HHEX rs1111875
(A > G)
0.33 0.29 Patient 234 (46.8) 200 (40.0) 66 (13.2) 0.039
1.61 (1.02–2.55)
0.082
1.55 (0.94–2.56)
0.260
1.16 (0.89–1.53)
0.367
1.14 (0.85–1.54)
0.044
1.56 (1.01–2.42)
0.087
1.51 (0.94–2.45)
Control 254 (50.8) 201 (40.2) 45 (9.0)
CDKAL1 rs7756992
(A > G)
0.43 0.40 Patient 156 (31.2) 257 (51.4) 87 (17.4) 0.249
1.27 (0.84–1.90)
0.107
1.44 (0.92–2.24)
0.355
1.14 (0.85–1.52)
0.169
1.25 (0.90–1.72)
0.340
1.19 (0.83–1.71)
0.182
1.30 (0.88–1.94)
Control 171 (34.2) 254 (50.8) 75 (15.0)
TCF7L2 rs7903146
(C > T)
0.08 0.04 Patient 429 (85.8) 67 (13.4) 4 (0.0) NA NA 0.006
1.80 (1.18–2.76)
0.025
1.70 (1.06–2.72)
NA NA
Control 456 (91.2) 44 (8.8) 0 (0.0)
MTNR1B rs1387153
(C > T)
0.44 0.42 Patient 164 (32.7) 232 (46.3) 104 (21.0) 0.113
1.35 (0.93–1.97)
0.120
1.38 (0.91–2.09)
0.618
1.07 (0.80–1.42)
0.757
1.05 (0.76–1.43)
0.058
1.38 (0.98–1.92)
0.047
1.44 (1.01–2.08)
Control 174 (34.8) 231 (46.2) 95 (19.0)
UBE2E2 rs7612463
(C > A)
0.83 0.82 Patient 346 (69.3) 134 (26.6) 20 (4.0) 0.875
0.94 (0.47–1.89)
0.855
0.93 (0.42–2.03)
0.890
0.95 (0.47–1.90)
0.872
0.93 (0.43–2.03)
0.847
0.97 (0.72–1.29)
0.826
0.96 (0.70–1.32)
Control 339 (67.8) 141 (28.2) 20 (4.0)
  1. Abbreviations: SNP single nucleotide polymorphism, T2D type 2 diabetes, Freqfrequency, A/A homo major allele, A/B heterozygote allele, B/B homo minor allele, OR odds ratio, CI confidence interval, NA not applicable (analytical model not applicable due to low frequency)
  2. A p < 0.006 (0.05 divided by 8, the total number of SNPs studied) was regarded as being statistically significant
  3. P-values were calculated for the additive, dominant, and recessive genetic models using logistic regression with/without adjustment for age, gender, and body mass index. The OR and 95% CI of having the risk allele are shown
  4. *Alleles in bold are the risk alleles for T2D identified in previous studies, while underlined alleles indicate the risk alleles for T2D observed in this study
  5. aRisk allele frequency in patients; bRisk allele frequency in controls; cStatistically significant after Bonferroni correction (multiple-testing) with p-value < 0.006